News

AmerisourceBergen Specialty Group revenues up 8%; key growth driver

BY Michael Johnsen

VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported that in its fiscal-year third quarter ended June 30, diluted earnings per share were 71 cents, an 8% increase over the prior-year quarter.

AmerisourceBergen’s Specialty Group had another strong quarter with revenues up 8%, driven by another particularly strong performance in third-party logistics and in the company’s vaccine and physician distribution business. Specialty Group represents significant opportunity for the wholesaler, Steven Collis, AmerisourceBergen president and CEO, told analysts.

"There’s a lot of opportunities to collaborate in those areas including with our Good Neighbor Pharmacy network and there’s an opportunity to do potentially more specialty in the community," he said. "We afford a lot of AmerisourceBergen customers that are interested in this area an opportunity to gain from our expertise, including in the policy area and the manufacturer relations area."

Within AmerisourceBergen’s specialty division, oncology is the core competency but the wholesaler is fast expanding into other specialty areas. "We have expanded [AmerisourceBergen’s oncology] capabilities to become an instrumental part of the commercialization strategy for any infusible product launched into the physician marketplace," Collis said.

AmerisouceBergen’s recent acquisition of World Courier is playing a key role within specialty. "The acquisition of World Courier has given us not only a premium quality clinical trial logistics services provider, but also an international framework upon which to further capitalize on our strengths by driving our specialty logistics, consulting, commercialization and reimbursement services into other geographic markets," Collis said.

AmerisourceBergen’s overall revenue in the quarter was $19.8 billion, down 1.9%. The company also narrowed the range of its expectations for the full fiscal year 2012 diluted earnings per share to $2.80 to $2.84 from its previous range of $2.74 to $2.84.

In third quarter 2012, Pharmaceutical Distribution revenues were $19.4 billion, a decrease of 3%, compared with the same quarter in the prior year. ABDC revenues declined 5%, due primarily to a decline in the volume of sales to the wholesaler’s largest customer, the anniversary of a significant customer win during last year’s third quarter and the previously announced loss of a large retail customer.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

McLane to acquire Meadowbrook Meat Co.

BY Allison Cerra

TEMPLE, Texas — McLane has entered into an agreement to acquire Meadowbrook Meat Co.

McLane said MBM — which is one of the nation’s largest customized foodservice distributors for national restaurant chains — will continue to be led by the current executive management team and operating out of its existing facilities in the same markets. McLane’s acquisition is subject to customary closing conditions, including the termination of the applicable waiting period under the Hart-Scott-Rodino Act.

"The Wordsworth family has built one of the finest and most highly respected companies in our industry, and we look forward to providing Jerry Wordsworth and his team our full support to continue MBM’s leadership in the market, while positioning ourselves for further growth," McLane CEO Grady Rosier said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Mylan launches antifungal drug

BY Alaric DeArment

PITTSBURGH — Mylan has launched a generic drug for treating fungal infections, the drug maker said Friday.

Mylan announced the launch of itraconazole capsules in the 100-mg strength. The drug is a generic version of Johnson & Johnson’s Sporanox, which is used to treat fungal infections that begin in the lungs blatsomycosis, histoplasmosis and aspergillosis in patients who are intolerant of or refractory to amphotericin B therapy. The drug also is used to treat fungal infections in the toenails and fingernails in patients without compromised immune systems.

The drug had sales of about $60 million during the 12-month period ended in March, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?